Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Liabilities (2021 - 2025)

Kiniksa Pharmaceuticals International's Other Non-Current Liabilities history spans 5 years, with the latest figure at $18.5 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 916.02% year-over-year to $18.5 million; the TTM value through Dec 2025 reached $18.5 million, up 916.02%, while the annual FY2025 figure was $18.5 million, 916.02% up from the prior year.
  • Other Non-Current Liabilities reached $18.5 million in Q4 2025 per KNSA's latest filing, up from $14.5 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $18.5 million in Q4 2025 to a low of $260000.0 in Q2 2022.
  • Average Other Non-Current Liabilities over 5 years is $3.5 million, with a median of $1.9 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 77.21% in 2022, then surged 916.02% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $270000.0 in 2021, then surged by 581.11% to $1.8 million in 2022, then rose by 1.03% to $1.9 million in 2023, then fell by 1.88% to $1.8 million in 2024, then soared by 916.02% to $18.5 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Other Non-Current Liabilities are $18.5 million (Q4 2025), $14.5 million (Q3 2025), and $9.3 million (Q2 2025).